Corrigendum to 'The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study' [Eur J Heart Fail 2022;24:205-214].
|
Join CureHunter, for free Research Interface BASIC access!Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.Realize the full power of the drug-disease research graph!
|